Elanco FY26 Q2 adjusted EPS rises 31% to $0.34; revenue increases 10% to $1.37 billion

Zenrelia became the largest contributor to global growth, followed by Credelio Quattro; Befrena shipped to nearly 1,400 U.S. clinics.

Full-year guidance rose to revenue of USD 5.09 billion-USD 5.14 billion, adjusted EBITDA of USD 1.01 billion-USD 1.04 billion, adjusted EPS of USD 1.10-USD 1.16.

Elanco Animal Health posted Q2 GAAP net income of USD 54 million, up from USD 11 million; GAAP EPS rose to USD 0.11 from USD 0.02.

Revenue climbed 10% from a year earlier to USD 1.37 billion, driven by Pet Health sales of USD 718 million, up 12%.

Adjusted EBITDA increased 21% to USD 288 million; adjusted EBITDA margin widened 2 percentage points to 21.2%.